Product image of Nilotinib Zentiva (Nilotinib) supplied by GNH India

Nilotinib Zentiva

Active Ingredient:
Nilotinib
Origin:
EU

Nilotinib Zentiva (Nilotinib)

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It selectively blocks the BCR‑ABL kinase and is indicated for treatment of Philadelphia chromosome‑positive chronic myeloid leukemia in adult patients.\n\nGNH India supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Zentiva Portugal, Lda

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Nilotinib targets the BCR‑ABL driven pathway in chronic myeloid leukemia and is used across disease phases.\n\n- Chronic phase CML: reduces leukemic cell proliferation and achieves cytogenetic response.\n- Accelerated phase CML: helps attain hematologic and molecular remission when used as monotherapy or in combination.\n- Blast phase CML: employed as part of multi‑agent regimens to suppress BCR‑ABL activity and improve survival outcomes.

How It Works

  • Nilotinib binds competitively to the ATP‑binding site of the BCR‑ABL fusion protein, inhibiting its tyrosine kinase activity. This blockade prevents downstream signaling that drives uncontrolled proliferation of leukemic cells, leading to apoptosis and reduced disease progression in Philadelphia chromosome‑positive chronic myeloid leukemia.

Side Effects

  • Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.\n\nCommon Side Effects:\n- Rash or skin irritation\n- Nausea or vomiting\n- Diarrhea\n- Elevated liver enzymes\n- Fatigue or weakness\n- Muscle cramps\n\nSerious or Rare Side Effects:\n- Cardiovascular events such as arterial occlusion\n- QT interval prolongation leading to arrhythmia\n- Severe pancreatitis or hepatic failure

Precautions & Warnings

  • Nilotinib requires careful monitoring and specific precautions before and during therapy.\n\n- Dose adjustment in hepatic impairment: reduce dose based on liver function tests.\n- Monitor cardiovascular health: assess for peripheral arterial disease and ischemic events.\n- Evaluate QT interval: obtain baseline ECG and repeat periodically.\n- Avoid in patients with active severe pancreatitis: discontinue if pancreatitis develops.\n- Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

  • Nilotinib can interact with several concomitant medicines, influencing its safety and efficacy.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce nilotinib exposure.\n- Proton pump inhibitors taken within 2 hours of nilotinib: decrease absorption.\n- Anticoagulants (e.g., warfarin): increased bleeding risk due to altered metabolism.\n\nModerate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may raise plasma levels, consider dose adjustment.\n- Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of myopathy, monitor lipid‑lowering therapy.

Frequently Asked Questions

Nilotinib Zentiva is prescribed for adult patients with Philadelphia chromosome‑positive chronic myeloid leukemia (CML). It is indicated across the chronic, accelerated, and blast phases of CML to inhibit the BCR‑ABL tyrosine kinase that drives disease progression.

Nilotinib selectively binds to the ATP‑binding pocket of the BCR‑ABL fusion protein, blocking its tyrosine kinase activity. This inhibition stops downstream signaling pathways that promote uncontrolled cell growth, leading to reduced proliferation of leukemic cells and induction of apoptosis.

The exact dose of Nilotinib Zentiva is individualized by the prescribing physician based on factors such as disease phase, patient weight, liver function, and potential drug interactions. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for nilotinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy and breastfeeding unless the potential benefit outweighs the risk, and it should only be prescribed by a specialist after thorough risk assessment.

To order Nilotinib Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor and is generally more potent than the first‑generation drug imatinib. It offers higher rates of molecular response in many patients, but it also carries a distinct safety profile, including a higher risk of cardiovascular events and QT prolongation, requiring careful monitoring.

Store Nilotinib Zentiva at room temperature, below 25 °C, in its original container. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout the shelf life.

Nilotinib Zentiva is taken orally, usually with a low‑fat meal to improve absorption. The tablets should be swallowed whole with water and not crushed or chewed. Patients must follow the dosing schedule prescribed by their healthcare provider.

Serious risks include cardiovascular events such as arterial occlusion, QT interval prolongation that can lead to life‑threatening arrhythmias, severe liver toxicity, and pancreatitis. Patients should report chest pain, irregular heartbeat, jaundice, or severe abdominal pain to their physician promptly.

Nilotinib is contraindicated in patients with known hypersensitivity to nilotinib or any of its excipients, those with a history of severe QT prolongation, uncontrolled cardiovascular disease, or active severe pancreatitis. It should also be avoided in individuals taking strong CYP3A4 inducers without appropriate dose adjustments.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nilotinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT